Early Detection of Prostate Cancer by FACS
Early Detection of Prostate Cancer by FACS
Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information
Basic Trial Information
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Diagnostic
Active
60 to 90
Other
HP 7-251 S
NCT00524823
Trial Description
Summary
Early detection of prostrate cancer and development of metastases. The research will attempt to match the SCM test (structuredness of the cytoplasmic matrix) in lymphocytes as an early cancer detection test using Florescent Activated Cell Sorting (FACS) as a replacement for the CellScan instrument. The test is based on measurement of cellular changes in response to the specific prostate antigen, PSA.
Eligibility Criteria
Inclusion Criteria:
Experimental group : Males between the ages of 60-90 years, with medical diagnosis of prostate cancer according to both clinical and hematological examinations, before receiving any medical treatment.
Control Group 1: Males between the ages of 60-90 years, with diagnosed benign prostate hyperplasia -BPH.
Control Group 2: Males between the ages of 60-90 years, medically diagnosed as healthy.
Control Group 3: Males between the ages of 60-90 years, medically diagnosed with another form of cancer, not prostate.
Exclusion Criteria:
Experimental group: Other known cancer or systemic infection. Control Group 1: Other known cancer or systemic infection. Control Group 2:Past hematological disorders nor cancer growth history. other known systemic infection, nor urinary tract infection. Patients hospitalized for orthopedic injuries of any type who are otherwise free of urinary tract infections.
Control Group 3:Other known systemic infection, nor urinary tract infection.
Trial Contact Information
Trial Lead Organizations/Sponsors
Rivka Ziv Hospital
Nina Kucherski, MD Principal Investigator
Nina Kucherski, MD Ph: 050-8434041
Yihia Johari, MD Ph: 050-8434094
Trial Sites
Israel
Safed
Votes:35
Comments: 0